Back to top
more

MorphoSys (MOR)

(Delayed Data from NSDQ)

$18.04 USD

18.04
388,329

-0.09 (-0.50%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $18.05 +0.01 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Balance Sheet

Research for MOR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for MorphoSys AG Unsponsored ADR falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 739 956 1,176 503 73
Receivables 42 112 94 98 19
Notes Receivable 0 0 0 0 0
Inventories 67 26 25 11 0
Other Current Assets 33 54 47 766 248
Total Current Assets 881 1,147 1,340 1,379 340
Net Property & Equipment 4 6 8 7 5
Investments & Advances 3 6 0 0 16
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 221 152 0
Intangibles 1,284 1,309 1,389 81 50
Deposits & Other Assets 9 9 16 226 96
Total Assets 2,193 2,525 3,024 1,896 556
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 119 166 223 147 64
Current Portion Long-Term Debt 2 2 1 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 1 1 0 0
Other Current Liabilities 162 117 109 78 2
Total Current Liabilities 286 293 337 229 69
Mortgages 0 0 0 0 0
Deferred Taxes/Income 7 7 26 6 0
Convertible Debt 264 307 335 312 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1,573 1,712 1,991 592 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,140 2,360 2,735 1,186 114
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 41 36 41 38 36
Capital Surplus 1,015 878 986 856 704
Retained Earnings -1,097 -868 -795 -180 -286
Other Equity 96 122 62 3 -1
Treasury Stock 2 3 4 6 9
Total Shareholder's Equity 53 166 290 710 442
Total Liabilities & Shareholder's Equity 2,193 2,525 3,024 1,896 556
Total Common Equity 53 166 290 710 442
Shares Outstanding 150.60 136.90 136.90 131.50 126.70
Book Value Per Share 0.35 1.21 2.12 5.40 3.49

Fiscal Year End for MorphoSys AG Unsponsored ADR falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 739 204 733 850
Receivables NA 42 64 94 84
Notes Receivable NA 0 1 0 0
Inventories NA 67 77 78 38
Other Current Assets NA 33 523 36 48
Total Current Assets NA 881 869 941 1,019
Net Property & Equipment NA 4 5 5 6
Investments & Advances NA 3 1 3 3
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 1,284 1,359 1,330 1,309
Deposits & Other Assets NA 9 10 10 9
Total Assets NA 2,193 2,287 2,336 2,393
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 119 127 131 160
Current Portion Long-Term Debt NA 2 2 2 2
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 1 1 1
Other Current Liabilities NA 162 143 126 116
Total Current Liabilities NA 286 277 264 283
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 7 7 7 7
Convertible Debt NA 264 264 261 255
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 1,773 1,730 1,704
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 2,140 2,360 2,302 2,289
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 41 37 37 37
Capital Surplus NA 1,015 918 918 896
Retained Earnings NA -1,097 -1,155 -1,027 -932
Other Equity NA 96 129 108 106
Treasury Stock NA 2 2 3 3
Total Shareholder's Equity NA 53 -73 35 104
Total Liabilities & Shareholder's Equity NA 2,193 2,287 2,336 2,393
Total Common Equity 0 53 -73 35 104
Shares Outstanding 150.60 150.60 NA 136.90 136.90
Book Value Per Share 0.00 0.35 0.00 0.25 0.76